According to CNBC, Novartis has raised its combined peak sales forecast for three drugs—Kesimpta, Scemblix, and Leqvio—to $18 billion from a previous $14 billion, citing strong commercial performance and improving demand. The company also projects an annual sales growth of approximately 5% through 2031; its previous guidance was 5% to 6% growth through 2030. Since the two periods cover different timeframes, they cannot be directly compared on a like-for-like basis.